We are live on ! Find out more
GILD icon

Gilead Sciences

1,525 hedge funds and large institutions have $66.4B invested in Gilead Sciences in 2017 Q1 according to their latest regulatory filings, with 133 funds opening new positions, 601 increasing their positions, 701 reducing their positions, and 157 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.66% less ownership

Funds ownership: 75.43%74.76% (-0.66%)

3% less funds holding

Funds holding: 1,5731,525 (-48)

3% less funds holding in top 10

Funds holding in top 10: 9188 (-3)

7% less capital invested

Capital invested by funds: $71.2B → $66.4B (-$4.83B)

14% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 701

15% less first-time investments, than exits

New positions opened: 133 | Existing positions closed: 157

35% less call options, than puts

Call options by funds: $1.45B | Put options by funds: $2.24B

Holders
1,525
Holders Change
-48
Holders Change %
-3.05%
% of All Funds
37.95%
Holding in Top 10
88
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-3.3%
% of All Funds
2.19%
New
133
Increased
601
Reduced
701
Closed
157
Calls
$1.45B
Puts
$2.24B
Net Calls
-$793M
Net Calls Change
-$355M
Name Holding Trade Value Shares
Change
Change in
Stake
PDM
326
Penn Davis McFarland
Texas
$13.3M +$1.07M +15,193 +8%
Daiwa Securities Group
327
Daiwa Securities Group
Japan
$13.3M +$5.52M +78,458 +67%
Cambridge Investment Research Advisors
328
Cambridge Investment Research Advisors
Iowa
$13M +$4.04M +57,423 +43%
Edgewood Management
329
Edgewood Management
Connecticut
$13M -$461K -6,556 -3%
LTFS
330
Ladenburg Thalmann Financial Services
Florida
$12.9M +$1.17M +16,596 +10%
BNP Paribas Asset Management
331
BNP Paribas Asset Management
France
$12.9M -$36.9M -525,064 -73%
ZIG
332
Zurich Insurance Group
Switzerland
$12.7M -$359K -5,108 -3%
AIM
333
Achmea Investment Management
Netherlands
$12.7M +$13.1M +186,661 New
CIM
334
Chiron Investment Management
New York
$12.7M +$13.1M +186,500 New
CC
335
Cognios Capital
Kansas
$12.6M +$5.71M +81,219 +77%
Janus Henderson Group
336
Janus Henderson Group
United Kingdom
$12.4M -$113K -1,610 -0.9%
BPC
337
Banque Pictet & Cie
Switzerland
$12.4M +$2.4M +34,140 +23%
ISL
338
Ingalls & Snyder LLC
New York
$12.4M +$1.85M +26,332 +17%
IAM
339
Impax Asset Management
New Hampshire
$12.3M +$703K +10,002 +6%
MIM
340
Marco Investment Management
Georgia
$12.3M +$3.14M +44,627 +33%
MSA
341
Mason Street Advisors
Wisconsin
$12.3M +$28.5K +405 +0.2%
RT
342
Rockland Trust
Massachusetts
$12.1M +$1.8M +25,551 +17%
WI
343
Wafra Inc
New York
$12.1M +$12.5M +178,246 New
SIM
344
Spark Investment Management
New York
$12.1M +$6.47M +92,000 +108%
NIM
345
Needham Investment Management
New York
$11.9M -$35.2K -500 -0.3%
NB
346
Norinchukin Bank
Japan
$11.8M +$497K +7,070 +4%
FWIA
347
Fort Washington Investment Advisors
Ohio
$11.5M -$465K -6,611 -4%
HBWM
348
Hollow Brook Wealth Management
New York
$11.5M -$1.4M -19,911 -11%
WF
349
Welch & Forbes
Massachusetts
$11.5M -$5.44M -77,402 -31%
UIM
350
Underhill Investment Management
California
$11.5M +$5.9M +83,850 +99%

GILD Hedge Fund Activity: Q1 2017 in Review

1,525 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2017, worth a combined $66.4B — down 6.8% from $71.2B a quarter earlier.

Sellers outnumbered buyers: 157 funds closed out of GILD and 133 opened new positions — a net loss of 24 holders — while 701 trimmed existing stakes and 601 added.

The largest buyer was BlackRock, adding an estimated $6.99B. The largest seller was Fidelity Investments, cutting an estimated $1.15B.

  • 1,525 institutional investors held Gilead Sciences (GILD) as of Q1 2017, down from 1,573 in Q4 2016.
  • Funds reported $66.4B of Gilead Sciences stock for Q1 2017, down 6.8% quarter-over-quarter.
  • 133 funds opened new Gilead Sciences positions in Q1 2017 and 157 closed out, a net change of -24 holders.
  • The largest Gilead Sciences buyer in Q1 2017 was BlackRock, an estimated $6.99B added.
  • The largest Gilead Sciences seller in Q1 2017 was Fidelity Investments, an estimated $1.15B sold.

Based on aggregated 13F filings for Q1 2017.